{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [["Adverse drug reactions", "Anesthesia", "Blood pressure", "Genetic polymorphism", "Nitric oxide"]], "CitationSubset": ["IM"], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "33410970", "DateCompleted": {"Year": "2021", "Month": "11", "Day": "15"}, "DateRevised": {"Year": "2021", "Month": "11", "Day": "15"}, "Article": {"Language": ["eng"], "ArticleDate": [{"Year": "2021", "Month": "01", "Day": "07"}], "ELocationID": ["10.1007/s00228-020-03059-9"], "Journal": {"ISSN": "1432-1041", "JournalIssue": {"Volume": "77", "Issue": "6", "PubDate": {"Year": "2021", "Month": "Jun"}}, "Title": "European journal of clinical pharmacology", "ISOAbbreviation": "Eur J Clin Pharmacol"}, "ArticleTitle": "Arginase II polymorphisms modify the hypotensive responses to propofol by affecting nitric oxide bioavailability.", "Pagination": {"StartPage": "869", "EndPage": "877", "MedlinePgn": "869-877"}, "Abstract": {"AbstractText": ["Propofol anesthesia is usually accompanied by hypotensive responses, which are at least in part mediated by nitric oxide (NO). Arginase I (ARG1) and arginase II (ARG2) compete with NO synthases for their common substrate L-arginine, therefore influencing the NO formation. We examined here whether ARG1 and ARG2 genotypes and haplotypes affect the changes in blood pressure and NO bioavailability in response to propofol.", "Venous blood samples were collected from 167 patients at baseline and after 10\u00a0min of anesthesia with propofol. Genotypes were determined by polymerase chain reaction. Nitrite concentrations were measured by using an ozone-based chemiluminescence assay, while NO<sub>x</sub> (nitrites + nitrates) levels were determined by using the Griess reaction.", "We found that patients carrying the AG + GG genotypes for the rs3742879 polymorphism in ARG2 gene and the ARG2 GC haplotype show lower increases in nitrite levels and lower decreases in blood pressure after propofol anesthesia. On the other hand, subjects carrying the variant genotypes for the rs10483801 polymorphism in ARG2 gene show more intense decreases in blood pressure (CA genotype) and/or higher increases in nitrite levels (CA and AA genotypes) in response to propofol.", "Our results suggest that ARG2 variants affect the hypotensive responses to propofol, possibly by modifying NO bioavailability.", "NCT02442232."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP, Brazil."}, {"Identifier": [], "Affiliation": "Department of Medicine, Division of Cardiology, Wilf Family Cardiovascular Research Institute, Albert Einstein College of Medicine, New York, NY, USA."}], "LastName": "Oliveira-Paula", "ForeName": "Gustavo H", "Initials": "GH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Analyses, Toxicology and Food Science, School of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, SP, Brazil."}], "LastName": "Coeli-Lacchini", "ForeName": "Fernanda Borchers", "Initials": "FB"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Genetics, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP, Brazil."}], "LastName": "Ferezin", "ForeName": "Let\u00edcia Perticarrara", "Initials": "LP"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP, Brazil."}], "LastName": "Ferreira", "ForeName": "Graziele C", "Initials": "GC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Psychiatric Nursing and Human Sciences, Ribeirao Preto College of Nursing, University of Sao Paulo, Av. Bandeirantes, 3900, Ribeirao Preto, SP, 14040-902, Brazil."}], "LastName": "Pinheiro", "ForeName": "Lucas C", "Initials": "LC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Orthopedics and Anesthesiology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP, Brazil."}], "LastName": "Paula-Garcia", "ForeName": "Waynice N", "Initials": "WN"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Orthopedics and Anesthesiology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP, Brazil."}], "LastName": "Garcia", "ForeName": "Luis V", "Initials": "LV"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP, Brazil."}], "LastName": "Tanus-Santos", "ForeName": "Jose E", "Initials": "JE"}, {"Identifier": ["0000-0002-3738-2036"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Psychiatric Nursing and Human Sciences, Ribeirao Preto College of Nursing, University of Sao Paulo, Av. Bandeirantes, 3900, Ribeirao Preto, SP, 14040-902, Brazil. rlacchini@eerp.usp.br."}], "LastName": "Lacchini", "ForeName": "Riccardo", "Initials": "R"}], "DataBankList": [{"DataBankName": "ClinicalTrials.gov", "AccessionNumberList": ["NCT02442232"]}], "GrantList": [{"GrantID": "2018/18312-2", "Agency": "Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo", "Country": ""}, {"GrantID": "302241/2017-5", "Agency": "Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Germany", "MedlineTA": "Eur J Clin Pharmacol", "NlmUniqueID": "1256165", "ISSNLinking": "0031-6970"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Anesthetics, Intravenous"}, {"RegistryNumber": "0", "NameOfSubstance": "Nitrates"}, {"RegistryNumber": "0", "NameOfSubstance": "Nitrites"}, {"RegistryNumber": "31C4KY9ESH", "NameOfSubstance": "Nitric Oxide"}, {"RegistryNumber": "EC 3.5.3.1", "NameOfSubstance": "ARG1 protein, human"}, {"RegistryNumber": "EC 3.5.3.1", "NameOfSubstance": "ARG2 protein, human"}, {"RegistryNumber": "EC 3.5.3.1", "NameOfSubstance": "Arginase"}, {"RegistryNumber": "YI7VU623SF", "NameOfSubstance": "Propofol"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": [], "DescriptorName": "Aged"}, {"QualifierName": ["adverse effects", "pharmacokinetics"], "DescriptorName": "Anesthetics, Intravenous"}, {"QualifierName": ["genetics"], "DescriptorName": "Arginase"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Genotype"}, {"QualifierName": [], "DescriptorName": "Haplotypes"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["chemically induced"], "DescriptorName": "Hypotension"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}, {"QualifierName": ["blood"], "DescriptorName": "Nitrates"}, {"QualifierName": ["metabolism"], "DescriptorName": "Nitric Oxide"}, {"QualifierName": ["blood"], "DescriptorName": "Nitrites"}, {"QualifierName": [], "DescriptorName": "Polymerase Chain Reaction"}, {"QualifierName": [], "DescriptorName": "Polymorphism, Single Nucleotide"}, {"QualifierName": ["adverse effects", "pharmacokinetics"], "DescriptorName": "Propofol"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Irwin MG, Chung CKE, Ip KY, Wiles MD (2020) Influence of propofol-based total intravenous anaesthesia on peri-operative outcome measures: a narrative review. Anaesthesia 75(Suppl 1):e90\u2013e100. https://doi.org/10.1111/anae.14905", "ArticleIdList": ["10.1111/anae.14905", "31903578"]}, {"Citation": "Marik PE (2004) Propofol: therapeutic indications and side-effects. Curr Pharm Des 10(29):3639\u20133649. https://doi.org/10.2174/1381612043382846", "ArticleIdList": ["10.2174/1381612043382846", "15579060"]}, {"Citation": "Hug CC Jr, McLeskey CH, Nahrwold ML, Roizen MF, Stanley TH, Thisted RA, Walawander CA, White PF, Apfelbaum JL, Grasela TH et al (1993) Hemodynamic effects of propofol: data from over 25,000 patients. Anesth Analg 77(4 Suppl):S21\u2013S29", "ArticleIdList": ["8214693"]}, {"Citation": "de Wit F, van Vliet AL, de Wilde RB, Jansen JR, Vuyk J, Aarts LP, de Jonge E, Veelo DP, Geerts BF (2016) The effect of propofol on haemodynamics: cardiac output, venous return, mean systemic filling pressure, and vascular resistances. Br J Anaesth 116(6):784\u2013789. https://doi.org/10.1093/bja/aew126", "ArticleIdList": ["10.1093/bja/aew126", "27199311"]}, {"Citation": "Pagel PS, Warltier DC (1993) Negative inotropic effects of propofol as evaluated by the regional preload recruitable stroke work relationship in chronically instrumented dogs. Anesthesiology 78(1):100\u2013108. https://doi.org/10.1097/00000542-199301000-00015", "ArticleIdList": ["10.1097/00000542-199301000-00015", "8424542"]}, {"Citation": "Robinson BJ, Ebert TJ, O\u2019Brien TJ, Colinco MD, Muzi M (1997) Mechanisms whereby propofol mediates peripheral vasodilation in humans: sympathoinhibition or direct vascular relaxation? Anesthesiology 86(1):64\u201372. https://doi.org/10.1097/00000542-199701000-00010", "ArticleIdList": ["10.1097/00000542-199701000-00010", "9009941"]}, {"Citation": "Rouby JJ, Andreev A, Leger P, Arthaud M, Landault C, Vicaut E, Maistre G, Eurin J, Gandjbakch I, Viars P (1991) Peripheral vascular effects of thiopental and propofol in humans with artificial hearts. Anesthesiology 75(1):32\u201342. https://doi.org/10.1097/00000542-199107000-00007", "ArticleIdList": ["10.1097/00000542-199107000-00007", "2064057"]}, {"Citation": "Gragasin FS, Davidge ST (2009) The effects of propofol on vascular function in mesenteric arteries of the aging rat. Am J Physiol Heart Circ Physiol 297(1):H466\u2013H474. https://doi.org/10.1152/ajpheart.01317.2008", "ArticleIdList": ["10.1152/ajpheart.01317.2008", "19465540"]}, {"Citation": "Oliveira-Paula GH, Lacchini R, Tanus-Santos JE (2016) Endothelial nitric oxide synthase: from biochemistry and gene structure to clinical implications of NOS3 polymorphisms. Gene 575(2 Pt 3):584\u2013599. https://doi.org/10.1016/j.gene.2015.09.061", "ArticleIdList": ["10.1016/j.gene.2015.09.061", "26428312"]}, {"Citation": "Oliveira-Paula GH, Lacchini R, Tanus-Santos JE (2017) Clinical and pharmacogenetic impact of endothelial nitric oxide synthase polymorphisms on cardiovascular diseases. Nitric Oxide 63:39\u201351. https://doi.org/10.1016/j.niox.2016.08.004", "ArticleIdList": ["10.1016/j.niox.2016.08.004", "27569446"]}, {"Citation": "Wang Y, Zhou H, Wu B, Zhou Q, Cui D, Wang L (2015) Protein kinase C isoforms distinctly regulate propofol-induced endothelium-dependent and endothelium-independent vasodilation. J Cardiovasc Pharmacol 66(3):276\u2013284. https://doi.org/10.1097/FJC.0000000000000275", "ArticleIdList": ["10.1097/FJC.0000000000000275", "25970840"]}, {"Citation": "Wang L, Wu B, Sun Y, Xu T, Zhang X, Zhou M, Jiang W (2010) Translocation of protein kinase C isoforms is involved in propofol-induced endothelial nitric oxide synthase activation. Br J Anaesth 104(5):606\u2013612. https://doi.org/10.1093/bja/aeq064", "ArticleIdList": ["10.1093/bja/aeq064", "20348139"]}, {"Citation": "Oliveira-Paula GH, Pinheiro LC, Ferreira GC, Garcia WNP, Lacchini R, Garcia LV, Tanus-Santos JE (2018) Angiotensin converting enzyme inhibitors enhance the hypotensive effects of propofol by increasing nitric oxide production. Free Radic Biol Med 115:10\u201317. https://doi.org/10.1016/j.freeradbiomed.2017.11.010", "ArticleIdList": ["10.1016/j.freeradbiomed.2017.11.010", "29138017"]}, {"Citation": "Kleinbongard P, Dejam A, Lauer T, Jax T, Kerber S, Gharini P, Balzer J, Zotz RB, Scharf RE, Willers R, Schechter AN, Feelisch M, Kelm M (2006) Plasma nitrite concentrations reflect the degree of endothelial dysfunction in humans. Free Radic Biol Med 40(2):295\u2013302. https://doi.org/10.1016/j.freeradbiomed.2005.08.025", "ArticleIdList": ["10.1016/j.freeradbiomed.2005.08.025", "16413411"]}, {"Citation": "Kleinbongard P, Dejam A, Lauer T, Rassaf T, Schindler A, Picker O, Scheeren T, Godecke A, Schrader J, Schulz R, Heusch G, Schaub GA, Bryan NS, Feelisch M, Kelm M (2003) Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. Free Radic Biol Med 35(7):790\u2013796. https://doi.org/10.1016/s0891-5849(03)00406-4", "ArticleIdList": ["10.1016/s0891-5849(03)00406-4", "14583343"]}, {"Citation": "Vanhoutte PM, Zhao Y, Xu A, Leung SW (2016) Thirty years of saying NO: sources, fate, actions, and misfortunes of the endothelium-derived vasodilator mediator. Circ Res 119(2):375\u2013396. https://doi.org/10.1161/CIRCRESAHA.116.306531", "ArticleIdList": ["10.1161/CIRCRESAHA.116.306531", "27390338"]}, {"Citation": "Pernow J, Jung C (2013) Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal? Cardiovasc Res 98(3):334\u2013343. https://doi.org/10.1093/cvr/cvt036", "ArticleIdList": ["10.1093/cvr/cvt036", "23417041"]}, {"Citation": "Caldwell RW, Rodriguez PC, Toque HA, Narayanan SP, Caldwell RB (2018) Arginase: a multifaceted enzyme important in health and disease. Physiol Rev 98(2):641\u2013665. https://doi.org/10.1152/physrev.00037.2016", "ArticleIdList": ["10.1152/physrev.00037.2016", "29412048", "5966718"]}, {"Citation": "Durante W, Johnson FK, Johnson RA (2007) Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol 34(9):906\u2013911. https://doi.org/10.1111/j.1440-1681.2007.04638.x", "ArticleIdList": ["10.1111/j.1440-1681.2007.04638.x", "17645639", "1955221"]}, {"Citation": "Berkowitz DE, White R, Li D, Minhas KM, Cernetich A, Kim S, Burke S, Shoukas AA, Nyhan D, Champion HC, Hare JM (2003) Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 108(16):2000\u20132006. https://doi.org/10.1161/01.CIR.0000092948.04444.C7", "ArticleIdList": ["10.1161/01.CIR.0000092948.04444.C7", "14517171"]}, {"Citation": "Zhang C, Hein TW, Wang W, Miller MW, Fossum TW, McDonald MM, Humphrey JD, Kuo L (2004) Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension 44(6):935\u2013943. https://doi.org/10.1161/01.HYP.0000146907.82869.f2", "ArticleIdList": ["10.1161/01.HYP.0000146907.82869.f2", "15492130"]}, {"Citation": "Rodriguez S, Richert L, Berthelot A (2000) Increased arginase activity in aorta of mineralocorticoid-salt hypertensive rats. Clin Exp Hypertens 22(1):75\u201385. https://doi.org/10.1081/ceh-100100063", "ArticleIdList": ["10.1081/ceh-100100063", "10685726"]}, {"Citation": "Michell DL, Andrews KL, Chin-Dusting JP (2011) Endothelial dysfunction in hypertension: the role of arginase. Front Biosci (Schol Ed) 3:946\u2013960. https://doi.org/10.2741/199", "ArticleIdList": ["10.2741/199"]}, {"Citation": "Demougeot C, Prigent-Tessier A, Marie C, Berthelot A (2005) Arginase inhibition reduces endothelial dysfunction and blood pressure rising in spontaneously hypertensive rats. J Hypertens 23(5):971\u2013978. https://doi.org/10.1097/01.hjh.0000166837.78559.93", "ArticleIdList": ["10.1097/01.hjh.0000166837.78559.93", "15834282"]}, {"Citation": "Bagnost T, Berthelot A, Bouhaddi M, Laurant P, Andre C, Guillaume Y, Demougeot C (2008) Treatment with the arginase inhibitor N(omega)-hydroxy-nor-L-arginine improves vascular function and lowers blood pressure in adult spontaneously hypertensive rat. J Hypertens 26(6):1110\u20131118. https://doi.org/10.1097/HJH.0b013e3282fcc357", "ArticleIdList": ["10.1097/HJH.0b013e3282fcc357", "18475148"]}, {"Citation": "Prieto CP, Krause BJ, Quezada C, San Martin R, Sobrevia L, Casanello P (2011) Hypoxia-reduced nitric oxide synthase activity is partially explained by higher arginase-2 activity and cellular redistribution in human umbilical vein endothelium. Placenta 32(12):932\u2013940. https://doi.org/10.1016/j.placenta.2011.09.003", "ArticleIdList": ["10.1016/j.placenta.2011.09.003", "21962305"]}, {"Citation": "Lacchini R, Muniz JJ, Nobre Y, Cologna AJ, Martins ACP, Tanus-Santos JE (2018) Influence of arginase polymorphisms and arginase levels/activity on the response to erectile dysfunction therapy with sildenafil. Pharmacogenomics J 18(2):238\u2013244. https://doi.org/10.1038/tpj.2017.2", "ArticleIdList": ["10.1038/tpj.2017.2", "28374859"]}, {"Citation": "Salam MT, Bastain TM, Rappaport EB, Islam T, Berhane K, Gauderman WJ, Gilliland FD (2011) Genetic variations in nitric oxide synthase and arginase influence exhaled nitric oxide levels in children. Allergy 66(3):412\u2013419. https://doi.org/10.1111/j.1398-9995.2010.02492.x", "ArticleIdList": ["10.1111/j.1398-9995.2010.02492.x", "21039601"]}, {"Citation": "Litonjua AA, Lasky-Su J, Schneiter K, Tantisira KG, Lazarus R, Klanderman B, Lima JJ, Irvin CG, Peters SP, Hanrahan JP, Liggett SB, Hawkins GA, Meyers DA, Bleecker ER, Lange C, Weiss ST (2008) ARG1 is a novel bronchodilator response gene: screening and replication in four asthma cohorts. Am J Respir Crit Care Med 178(7):688\u2013694. https://doi.org/10.1164/rccm.200709-1363OC", "ArticleIdList": ["10.1164/rccm.200709-1363OC", "18617639", "2556451"]}, {"Citation": "Ma Q, Wyszynski DF, Farrell JJ, Kutlar A, Farrer LA, Baldwin CT, Steinberg MH (2007) Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea. Pharmacogenomics J 7(6):386\u2013394. https://doi.org/10.1038/sj.tpj.6500433", "ArticleIdList": ["10.1038/sj.tpj.6500433", "17299377"]}, {"Citation": "Vonk JM, Postma DS, Maarsingh H, Bruinenberg M, Koppelman GH, Meurs H (2010) Arginase 1 and arginase 2 variations associate with asthma, asthma severity and beta2 agonist and steroid response. Pharmacogenet Genomics 20(3):179\u2013186. https://doi.org/10.1097/FPC.0b013e328336c7fd", "ArticleIdList": ["10.1097/FPC.0b013e328336c7fd", "20124949"]}, {"Citation": "Bryson HM, Fulton BR, Faulds D (1995) Propofol. An update of its use in anaesthesia and conscious sedation. Drugs 50(3):513\u2013559. https://doi.org/10.2165/00003495-199550030-00008", "ArticleIdList": ["10.2165/00003495-199550030-00008", "8521772"]}, {"Citation": "Claeys MA, Gepts E, Camu F (1988) Haemodynamic changes during anaesthesia induced and maintained with propofol. Br J Anaesth 60(1):3\u20139. https://doi.org/10.1093/bja/60.1.3", "ArticleIdList": ["10.1093/bja/60.1.3", "3257393"]}, {"Citation": "Wang H, Kuo TB, Chan SH, Tsai TH, Lee TY, Lui PW (1996) Spectral analysis of arterial pressure variability during induction of propofol anesthesia. Anesth Analg 82(5):914\u2013919. https://doi.org/10.1097/00000539-199605000-00004", "ArticleIdList": ["10.1097/00000539-199605000-00004", "8610898"]}, {"Citation": "Metzger IF, Sertorio JT, Tanus-Santos JE (2006) Relationship between systemic nitric oxide metabolites and cyclic GMP in healthy male volunteers. Acta Physiol (Oxford) 188(2):123\u2013127. https://doi.org/10.1111/j.1748-1716.2006.01612.x", "ArticleIdList": ["10.1111/j.1748-1716.2006.01612.x"]}, {"Citation": "Silva PS, Fontana V, Palei ACT, Sertorio JTC, Biagi C, Tanus-Santos JE (2011) Antihypertensive effects exerted by enalapril in mild to moderate hypertension are not associated with changes in the circulating levels of nitric oxide-related markers. Eur J Clin Pharmacol 67(4):365\u2013370. https://doi.org/10.1007/s00228-011-1003-x", "ArticleIdList": ["10.1007/s00228-011-1003-x", "21305271"]}, {"Citation": "Sinha S, Sinharoy P, Bratz IN, Damron DS (2015) Propofol causes vasodilation in vivo via TRPA1 ion channels: role of nitric oxide and BKCa channels. PLoS One 10(4):e0122189. https://doi.org/10.1371/journal.pone.0122189", "ArticleIdList": ["10.1371/journal.pone.0122189", "25830814", "4382130"]}, {"Citation": "Oliveira-Paula GH, Lacchini R, Pinheiro LC, Ferreira GC, Luizon MR, Garcia WNP, Garcia LV, Tanus-Santos JE (2018) Endothelial nitric oxide synthase polymorphisms affect the changes in blood pressure and nitric oxide bioavailability induced by propofol. Nitric Oxide 75:77\u201384. https://doi.org/10.1016/j.niox.2018.02.007", "ArticleIdList": ["10.1016/j.niox.2018.02.007", "29496565"]}, {"Citation": "Meroufel D, Dumont J, Mediene-Benchekor S, Benhammamouch S, Ducimetiere P, Cottel D, Montaye M, Amouyel P, Brousseau T (2009) Characterization of arginase 1 gene polymorphisms in the Algerian population and association with blood pressure. Clin Biochem 42(10\u201311):1178\u20131182. https://doi.org/10.1016/j.clinbiochem.2009.03.004", "ArticleIdList": ["10.1016/j.clinbiochem.2009.03.004", "19303401"]}, {"Citation": "Li H, Romieu I, Sienra-Monge JJ, Ramirez-Aguilar M, Estela Del Rio-Navarro B, Kistner EO, Gjessing HK, Lara-Sanchez Idel C, Chiu GY, London SJ (2006) Genetic polymorphisms in arginase I and II and childhood asthma and atopy. J Allergy Clin Immunol 117(1):119\u2013126. https://doi.org/10.1016/j.jaci.2005.09.026", "ArticleIdList": ["10.1016/j.jaci.2005.09.026", "16387594"]}, {"Citation": "Duan QL, Gaume BR, Hawkins GA, Himes BE, Bleecker ER, Klanderman B, Irvin CG, Peters SP, Meyers DA, Hanrahan JP, Lima JJ, Litonjua AA, Tantisira KG, Liggett SB (2011) Regulatory haplotypes in ARG1 are associated with altered bronchodilator response. Am J Respir Crit Care Med 183(4):449\u2013454. https://doi.org/10.1164/rccm.201005-0758OC", "ArticleIdList": ["10.1164/rccm.201005-0758OC", "20851928"]}, {"Citation": "Dumont J, Zureik M, Cottel D, Montaye M, Ducimetiere P, Amouyel P, Brousseau T (2007) Association of arginase 1 gene polymorphisms with the risk of myocardial infarction and common carotid intima media thickness. J Med Genet 44(8):526\u2013531. https://doi.org/10.1136/jmg.2006.047449", "ArticleIdList": ["10.1136/jmg.2006.047449", "17369504", "2597928"]}, {"Citation": "Lacchini R, Muniz JJ, Nobre YT, Cologna AJ, Martins AC, Tanus-Santos JE (2015) Relationship between Arginase 1 and Arginase 2 levels and genetic polymorphisms with erectile dysfunction. Nitric Oxide 51:36\u201342. https://doi.org/10.1016/j.niox.2015.10.003", "ArticleIdList": ["10.1016/j.niox.2015.10.003", "26537638"]}, {"Citation": "Salam MT, Islam T, Gauderman WJ, Gilliland FD (2009) Roles of arginase variants, atopy, and ozone in childhood asthma. J Allergy Clin Immunol 123(3):596\u2013602, 602 e591-598. https://doi.org/10.1016/j.jaci.2008.12.020", "ArticleIdList": ["10.1016/j.jaci.2008.12.020", "19281908", "2913574"]}, {"Citation": "Oliveira-Paula GH, Lacchini R, Luizon MR, Fontana V, Silva PS, Biagi C, Tanus-Santos JE (2016) Endothelial nitric oxide synthase tagSNPs influence the effects of enalapril in essential hypertension. Nitric Oxide 55-56:62\u201369. https://doi.org/10.1016/j.niox.2016.03.006", "ArticleIdList": ["10.1016/j.niox.2016.03.006", "27060232"]}, {"Citation": "Oliveira-Paula GH, Lacchini R, Coeli-Lacchini FB, Junior HM, Tanus-Santos JE (2013) Inducible nitric oxide synthase haplotype associated with hypertension and responsiveness to antihypertensive drug therapy. Gene 515(2):391\u2013395. https://doi.org/10.1016/j.gene.2012.12.059", "ArticleIdList": ["10.1016/j.gene.2012.12.059", "23266817"]}, {"Citation": "Crawford DC, Nickerson DA (2005) Definition and clinical importance of haplotypes. Annu Rev Med 56:303\u2013320. https://doi.org/10.1146/annurev.med.56.082103.104540", "ArticleIdList": ["10.1146/annurev.med.56.082103.104540", "15660514"]}, {"Citation": "Thomas DD, Liu X, Kantrow SP, Lancaster JR Jr (2001) The biological lifetime of nitric oxide: implications for the perivascular dynamics of NO and O2. Proc Natl Acad Sci U S A 98(1):355\u2013360. https://doi.org/10.1073/pnas.011379598", "ArticleIdList": ["10.1073/pnas.011379598", "11134509"]}, {"Citation": "Ellis G, Adatia I, Yazdanpanah M, Makela SK (1998) Nitrite and nitrate analyses: a clinical biochemistry perspective. Clin Biochem 31(4):195\u2013220. https://doi.org/10.1016/s0009-9120(98)00015-0", "ArticleIdList": ["10.1016/s0009-9120(98)00015-0", "9646943"]}, {"Citation": "Metzger IF, Luizon MR, Lacchini R, Ishizawa MH, Tanus-Santos JE (2013) Effects of endothelial nitric oxide synthase tagSNPs haplotypes on nitrite levels in black subjects. Nitric Oxide 28:33\u201338. https://doi.org/10.1016/j.niox.2012.10.002", "ArticleIdList": ["10.1016/j.niox.2012.10.002", "23069892"]}, {"Citation": "Oliveira-Paula GH, Luizon MR, Lacchini R, Fontana V, Silva PS, Biagi C, Tanus-Santos JE (2017) Gene-gene interactions among PRKCA, NOS3 and BDKRB2 polymorphisms affect the antihypertensive effects of enalapril. Basic Clin Pharmacol Toxicol 120(3):284\u2013291. https://doi.org/10.1111/bcpt.12682", "ArticleIdList": ["10.1111/bcpt.12682", "27696692"]}, {"Citation": "Visigalli R, Barilli A, Parolari A, Sala R, Rotoli BM, Bussolati O, Gazzola GC, Dall\u2019Asta V (2010) Regulation of arginine transport and metabolism by protein kinase Calpha in endothelial cells: stimulation of CAT2 transporters and arginase activity. J Mol Cell Cardiol 49(2):260\u2013270. https://doi.org/10.1016/j.yjmcc.2010.04.007", "ArticleIdList": ["10.1016/j.yjmcc.2010.04.007", "20430034"]}, {"Citation": "Oliveira-Paula GH, Lacchini R, Fontana V, Silva PS, Biagi C, Tanus-Santos JE (2015) Polymorphisms in VEGFA gene affect the antihypertensive responses to enalapril. Eur J Clin Pharmacol 71(8):949\u2013957. https://doi.org/10.1007/s00228-015-1872-5", "ArticleIdList": ["10.1007/s00228-015-1872-5", "26002049"]}, {"Citation": "Wang L, Bhatta A, Toque HA, Rojas M, Yao L, Xu Z, Patel C, Caldwell RB, Caldwell RW (2015) Arginase inhibition enhances angiogenesis in endothelial cells exposed to hypoxia. Microvasc Res 98:1\u20138. https://doi.org/10.1016/j.mvr.2014.11.002", "ArticleIdList": ["10.1016/j.mvr.2014.11.002", "25445030"]}], "ReferenceList": []}], "History": [{"Year": "2020", "Month": "8", "Day": "17"}, {"Year": "2020", "Month": "11", "Day": "26"}, {"Year": "2021", "Month": "1", "Day": "8", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "11", "Day": "16", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "1", "Day": "7", "Hour": "12", "Minute": "16"}], "PublicationStatus": "ppublish", "ArticleIdList": ["33410970", "10.1007/s00228-020-03059-9", "10.1007/s00228-020-03059-9"]}}], "PubmedBookArticle": []}